GLP-1 drugs like Ozempic and Wegovy are some of the biggest developments in global health in years.

Steve Wheen, Managing Director, Equity Research at Jarden, talks to Sean Aylmer about the investment opportunities associated with these drugs, and the potential risk to other companies in the healthcare sector.

This is Fear & Greed's summer investing series. All information is general in nature - you should seek independent professional advice before making investment decisions.

Support the show: http://fearandgreed.com.au/

See omnystudio.com/listener for privacy information.